Bertil Glader, MD
Pediatric Hematology-Oncology · Palo Alto
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 2
- 1 carrier
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plans that list them
2 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Glader’s office at (650) 497-8000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence G34194 · Current
Licensed to practise in California · since 1977 · expires 2027-04-30 · Northwestern University Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$6,112 in 2022
Medicaid paid $6,112 for 62 billed services this clinician did in 2022, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 50 | $5,233 |
| Return visit (30+ min) | 12 | $879 |
| 2022 | 62 | 2 | 18 | $6,112 |
| 2019 | 149 | 1 | 21 | $10,658 |
| 2018 | 215 | 2 | 20 | $14,585 |
See the largest Medicaid services in earlier years
2019
| Return visit (30+ min) | 149 | $10,658 |
2018
| Return visit (30+ min) | 200 | $14,073 |
| Service | 15 | $512 |
Money from drug and device companies
$203 in 2025
| 2025 | 2 | 3 | None | $203 |
| 2024 | 1 | 4 | None | $210 |
| 2023 | 1 | 9 | $4,440 | $4,645 |
| 2022 | 2 | 11 | $4,328 | $5,830 |
| 2020 | 2 | 10 | $13,005 | $13,129 |
| 2019 | 4 | 8 | $1,530 | $2,672 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alexion Pharmaceuticals | Ultomiris | $122 | 1 payment
|
| Agios Pharmaceuticals | Pyrukynd | $81 | 2 payments
|
See all 3 published payments
| Alexion Pharmaceuticals | Meals · 2025-06-26 | Ultomiris | $122 |
| Agios Pharmaceuticals | Meals · 2025-06-25 | Pyrukynd | $54 |
| Agios Pharmaceuticals | Meals · 2025-03-05 | Pyrukynd | $27 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $210
| Agios Pharmaceuticals | Pyrukynd | $210 | 4 payments
|
2023: $4,645
| Agios Pharmaceuticals | Pyrukynd | $4,645 | 9 payments
|
2022: $5,830
| Agios Pharmaceuticals | Pyrukynd | $5,705 | 10 payments
|
| Spark Therapeutics | None | $125 | 1 payment
|
2020: $13,129
| Agios Pharmaceuticals | None | $13,005 | 9 payments
|
| Spark Therapeutics | None | $124 | 1 payment
|
2019: $2,672
| Agios Pharmaceuticals | None | $1,530 | 1 payment
|
| BioMarin Pharmaceutical | None | $905 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $122 | 1 payment
|
| Genentech USA | Hemlibra | $116 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Agios Pharmaceuticals, Inc. · Pyrukynd · 2024 | Their institution | $171,060 |
| Agios Pharmaceuticals, Inc. · Pyrukynd · 2025 | Their institution | $102,953 |
| Agios Pharmaceuticals, Inc. · A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered Ag-348 in Healthy Volunteers · 2022 | Their institution | $94,143 |
| Agios Pharmaceuticals, Inc. · A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered Ag-348 in Healthy Volunteers · 2024 | Their institution | $91,197 |
| Agios Pharmaceuticals, Inc. · A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered Ag-348 in Healthy Volunteers · 2023 | Their institution | $75,371 |
| Agios Pharmaceuticals, Inc. · Pyrukynd · 2023 | Their institution | $62,714 |
| Agios Pharmaceuticals, Inc. · Pyruvatekinase Deficiency Global Longitudinal Registry · 2022 | Their institution | $14,419 |
| Agios Pharmaceuticals, Inc. · A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered Ag-348 in Healthy Volunteers · 2020 | Their institution | $14,100 |
| Agios Pharmaceuticals, Inc. · A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered Ag-348 in Healthy Volunteers · 2019 | Their institution | $9,040 |
| Agios Pharmaceuticals, Inc. · A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered Ag-348 in Healthy Volunteers · 2025 | Their institution | $4,548 |
| Agios Pharmaceuticals, Inc. · Pyruvatekinase Deficiency Global Longitudinal Registry · 2024 | Their institution | $4,529 |
| Agios Pharmaceuticals, Inc. · Pyruvatekinase Deficiency Global Longitudinal Registry · 2025 | Their institution | $3,848 |
| Agios Pharmaceuticals, Inc. · Pyruvatekinase Deficiency Global Longitudinal Registry · 2023 | Their institution | $3,236 |
| Agios Pharmaceuticals, Inc. · Investigator Sponsored Trial · 2024 | This clinician | $2,040 |
| Novartis Pharmaceuticals Corporation · A Phase II Open Label Non Controlled Intra Patient Doseescalation Study To Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory Relapsed Or Treatment Na?Ve Severe Aplastic Anemia Or Recurrent Apl · 2019 | Their institution | $350 |
Professional record
- NPI
- 1417082272
- Licence
- CA G34194California G34194: Current · expires 2027-04-30
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G341940
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X)
- Mailing address
- 2680 Hanover St, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-22
- NPI last updated
- 2008-03-24
This is when the NPI record was last certified, not a medical board exam.